- ***Duration of therapy*** with abiraterone acetate or enzalutamide w assessed as time from index date until the last date of all abirate acetate or enzalutamide treatment; this period includes treatmen (switched) medications and gaps in therapy. In addition, ***total da*** were calculated as the sum of days supply from filled prescriptio abiraterone acetate and enzalutamide.
- ***Hospice use*** was measured in medical claims based on proced for hospice services and site of service codes; time from index d evidence of hospice, and time from hospice to death were meas
- ***Mortality*** was assessed using the Social Security Master Death facility discharge status, and use of hospice services with subse plan disenrollment.
- Enrollment data were used to identify age, insurance type, and region of residence. Clinical characteristics were measured from and pharmacy claims, including Charlson Comorbidity Score[2], b metastases, docetaxel, and pre- and post-index statin use.

Analytic Methods

- Descriptive analyses compared ABI and ENZ on characteristics outcomes; t-tests for means and chi-square tests for dichotomo
- Cox proportional hazards compared ABI and ENZ on duration of with models adjusted for demographic and clinical characteristic
- Time to hospice and time from entering hospice until death were

References

1. Sartor O, Gillessen S. Treatment sequencing in metastatic castrate-resistant prostate cance 2014 May-Jun; 16(3): 426–431.
2. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Fe WA, Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative da

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.